Sildenafil y Coroidopatía Serosa Central. Reporte de Caso

Sildenafil y Coroidopatía Serosa Central. Reporte de Caso

Contenido principal del artículo

Ricardo Valdés
Oscar L. Ramirez
Francisco Ochoa
Jose F. Trujillo

Resumen

Purpose: to describe one case of concomitance of sildenafil intake and Central Serous Chorioretinopathy (CSC) in a 29 years male. Considerations about evolution and treatment are presented as well as a revision of the scarce literature found.


Conclusion: Concomitance between sildenafil and CSC is extremely rare, and as an adverse event can be classified just as “possible”. Evidence reports are not statically significant for this association although there is plausible hipothesis to support it.

Detalles del artículo

Biografía del autor/a (VER)

Ricardo Valdés, Clínica Ver Bien

Oftalmólogo Supra-Especialista en Retina y Vítreo

Oscar L. Ramirez, Clínica Ver Bien

Oftalmólogo

Francisco Ochoa, Clínica Ver Bien

Oftalmólogo

Jose F. Trujillo, Clínica Ver Bien

Oftalmólogo

Referencias (VER)

Systemic findings associated with central serous chorioretinopathy. Tittl MK, Spaide RF, Wong D, Pilotto E, Ya- nuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson. JA Am J Ophthalmol 1999; 128: 63–68 2. Central serous chorioretinopathy and glucocorticoids. Bouzas EA, Karadimas P, Pournaras. C J Surv Ophthalmol 2002; 47: 431– 448 3. Central Serous Chorioretinopathy in a Patient Taking Sildenafil Citrate. Zishan A Allibhai, Jeffrey S Gale, Thomas S Sheidow. Ophthalmic Surgery, Lasers and Imaging. 2004; 35 (2): 165 4. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Vance SK, Imamura Y, Freund KB. Retina. 2011; 31(2): 332-5 5. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Aliferis K, Petropoulos IK, Farpour B, Matter MA, Safran AB. Ophthalmologica. 2012; 227(2) pp. 85-9 6. Central ser ous chorior etinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. French DD, Margo CE. Retina. 2010; 30(2): 271-4

Central serous chorioretinopathy associated with sildenafil. Fraunfelder FW, Fraunfelder FT. Retina. 2008; Apr; 28(4): 606-9 8. US Viagra. Physician Prescribing Information and US Patient Product Information. Pfizer Labs LAB-0221-12.0. 2011. http://www.pfizer.com/ files/products/uspi_viagra.pdf 9. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. Lowe G, Costabile RA. J Sex Med. 2012; 9(1): 265-70 10. The effect of sildenafil on ocular blood flow. Harris A, Kagemann L, Ehrlich R, Ehrlich Y, López CR, Purvin VA. Br J Ophthalmol. 2008; 92(4): 469-73 11. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Retina. 2009; 29(10): 1469-73 12. Non-arteritic anterior iscahemic optic neuropathy and the treatment of erectile dysfunction. McGwin G, Jr, Vaphiades M S, Hall T A, Owsley C. Br J Ophthalmol 2006; 90: 154-157. 13. Pathogenesis of disciform detachment of the neuroepithelium. Gass JD. Am J Ophtalmol 1967; 63: Suppl: 1-139.